Dianthus Therapeutics, Inc. Common Stock (DNTH) is a publicly traded Healthcare sector company. As of May 21, 2026, DNTH trades at $88.72 with a market cap of $4.57B and a P/E ratio of -20.90. DNTH moved +3.53% today. Year to date, DNTH is +140.50%; over the trailing twelve months it is +364.26%. Its 52-week range spans $13.37 to $96.50. Analyst consensus is strong buy with an average price target of $122.57. Rallies surfaces DNTH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
DNTH financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. DNTH recently traded at $88.72. Market cap is $4.57B. P/E ratio is -20.90. Revenue is $1.34M.
| Metric | Value |
|---|---|
| Price | $88.72 |
| Market Cap | $4.57B |
| P/E Ratio | -20.90 |
| EPS | $-4.22 |
| Dividend Yield | 0.00% |
| 52-Week High | $96.50 |
| 52-Week Low | $13.37 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $1.34M |
| Net Income | $-173.66M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.04M | $-162.34M | $-4.20 |
| 2024 | $6.24M | $-84.97M | $-2.55 |
| 2023 | $2.83M | $-43.55M | $-8.45 |
15 analysts cover DNTH: 0 strong buy, 15 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $122.57.